Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in (Q80384676)
Jump to navigation
Jump to search
scientific article published on 01 August 2004
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in |
scientific article published on 01 August 2004 |
Statements
Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease (English)
Andrew J Palmer
Lieven Annemans
Stéphane Roze
Mark Lamotte
Pablo Lapuerta
Roland Chen
Sylvie Gabriel
Paulo Carita
Roger A Rodby
Dick de Zeeuw
Hans-Henrik Parving